“Darnitsa” employees study at Harvard Medical School

21 specialists from the pharmaceutical company “Darnitsa” have successfully completed courses at Harvard Medical School. At this university, students have access to the most up-to-date knowledge in the medical field, as this higher educational institution, founded in 1782, is one of the most authoritative and oldest medical schools in the world.

“Darnitsa” started cooperating with Harvard Medical School this year, as investment in the professional development of employees is one of the company`s priorities.

“Darnitsa” invests in the development of the talents of its employees. Studying at Harvard Medical School means access to the most up-to-date knowledge in the medical field, enhancing of professional level due to the best lecturers and an opportunity to study at one of the most exciting schools in the world. This year the project was pilot and having seen the results and the level of interest of the employees, we have decided to continue training of the employees at this higher educational institution in 2022”, - explains Olena Sokolova, HR Director of pharmaceutical company “Darnitsa”.

“Darnitsa” employees studied online in English. Each of them independently chose courses from the school`s catalogue dealing with the basics of pharmacology, immunology, physiology, new methods of chronic inflammation treatment, etc. On completion, all students took an exam to confirm their acquired knowledge and received a certificate from Harvard Medical School.

Every employee of “Darnitsa” has the opportunity to study at Harvard Medical School, regardless of his or her position. It is being actively used: there will be more than twice as many employees studying in 2022.

Reference

PJSC Pharmaceutical Company “Darnitsa” was founded in 1930. Since 1998, “Darnitsa” has been Ukraine’s leader in the production of medicines in volume terms. The strategic areas of portfolio development are cardiology, neurology and pain management. During 2015-2020, “Darnitsa” has launched 50 pharmaceutical brands on the market.